We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

  • Twitter
  • Facebook
  • LinkedIn
Biweekly newsletter of the International Cytokine & Interferon Society

Biweekly newsletter of the International Cytokine & Interferon Society

Signals+ Editors: Daniella Schwartz & Di Yu (Editors in Chief), Saurabh Chattopadhyay, Zhian Chen, Mohamed Saad & Maialen Sebastian-delaCruz

  • Subscribe
  • Archives
    • Archives (Oct. 2023 and before)
      • Signals+ October 2022 PDF
      • Signals+ April 2021 PDF
      • Signals+ April 2022 PDF
  • Awards
  • Annual Meeting
  • Member News
    • Member Highlights
    • Members in the News
    • Members on the Move
    • New Member Mini-Bios
    • Articles of Interest
    • Reviews of Interest
  • Society News
    • President’s Letter
    • Featured Article!
  • Industry News
    • Industry Partner News
    • Other Meetings
    • Clinical Trials
HomeTH17

TH17

Special Article of Interest

FOOD for THOUGHT: NEW T CELL SUBSETS?

April 25, 2022

FOOD for THOUGHT: NEW T CELL SUBSETS?

Dr. Dragana Jankovic
NIAID, NIH
[READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Photo of Amena Alrabeea in front of a waterfall
Member Highlights

Member Highlight: Meet Amenah Alrabeea, Ph.D.

June 2, 2025

My research focuses on understanding how cytokine signaling, particularly IL-6, influences disease progression and drug resistance. I’m in the process of setting up my lab at Kuwait University, where aim to study the differences between classical and trans-signaling pathways of IL-6, and how they activate cells in distinct ways. Ultimately, [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Photo of Suraj Gupta
New Member Mini-Bios

Suraj Gupta, Birla Institute of Technology and Science, Pilani – Hyderabad Campus

June 2, 2025

Mr. Suraj Gupta is a fourth-year PhD Research Scholar at the Department of Pharmacy, BITS Pilani Hyderabad Campus, India, working under the supervision of Professor Sajeli Begum. His research involves the development of novel small-molecule cytokine inhibitors. A passionate medicinal chemistry enthusiast, his journey began during his B.Pharm and M.Pharm [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Clinical Trials, contributed by Howard A. Young
Clinical Trials

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study (INCAS)

June 1, 2025

ClinicalTrials.gov ID NCT05653193 Sponsor Manchester University NHS Foundation Trust Information provided by Manchester University NHS Foundation Trust (Responsible Party) Brief Summary This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Clinical Trials, contributed by Howard A. Young
Clinical Trials

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

June 1, 2025

ClinicalTrials.gov ID NCT06130579 Sponsor Peking University People’s Hospital Information provided by Xiao-Jun Huang, Peking University People’s Hospital (Responsible Party) Brief Summary To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Clinical Trials, contributed by Howard A. Young
Clinical Trials

Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE

June 1, 2025

ClinicalTrials.gov ID NCT06586710 Sponsor Meyer Children’s Hospital IRCCS Information provided by Carmela Errichiello, Meyer Children’s Hospital IRCCS (Responsible Party) Brief Summary Pediatric SLE includes monogenic forms, some of which involve the interferon type I (IFN-I) pathway. The IFN-I pathway is renally active in adult SLE and correlates with the extent [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy